gilead yeztugo - Search News

News

HIV, Yeztugo and Gilead Sciences

Pharmaceutical Technology · 20m

Gilead Sciences’ Yeztugo receives approval from US FDA for HIV

The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against HIV.

Yahoo Finance · 13h

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg,

Barron's on MSN · 12h

FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who received it in large clinical trials. The drug, developed by Gilead Sciences and called Yeztugo,

Medical Dialogues2h

Gilead Sciences twice-yearly injection for HIV prevention bags USFDA okay

Gilead Sciences, Inc., a biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) ...

Fierce Pharma14h

FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results